TOP TEN perturbations for P98179 (Homo sapiens)
Organism: Homo sapiens
Gene: P98179
Selected probe(set): 208319_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of P98179 (208319_s_at) across 5610 perturbations tested by GENEVESTIGATOR:
HIV-associated neurocognitive disorder study 3 (HIVE) / HIV-associated neurocognitive disorder study 2 (HIVE)
Relative Expression (log2-ratio):-4.2518377Number of Samples:2 / 2
| Experimental | HIV-associated neurocognitive disorder study 3 (HIVE) |
| Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with HIV encephalitis (HIVE). HIVE was limited to the basal ganglia. The patients did not receive any antiretroviral therapy (ART). | |
| Control | HIV-associated neurocognitive disorder study 2 (HIVE) |
| Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with HIV encephalitis (HIVE). The patients received an antiretroviral therapy (ART). |
kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample
Relative Expression (log2-ratio):-4.0090675Number of Samples:2 / 5
| Experimental | kidney transplantation study 15 (8 week) |
| CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
| Control | normal monocyte (CD14+) sample |
| CD14+ monocyte samples derived from healthy control subjects. |
wound healing study 2 (ex vivo; AG1478) / normal skin tissue (ex vivo)
Relative Expression (log2-ratio):-2.9557724Number of Samples:3 / 3
| Experimental | wound healing study 2 (ex vivo; AG1478) |
| Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing AG1478 for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 10 micromolar AG1478 (dissolved in DMSO). The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin. AG1478 is EGFR kinase inhibitor. ATC code:--- | |
| Control | normal skin tissue (ex vivo) |
| Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. |
Parkinson's disease study 10 / normal postmortem substantia nigra tissue
Relative Expression (log2-ratio):-2.7523623Number of Samples:16 / 9
| Experimental | Parkinson's disease study 10 |
| Substantia nigra tissue from postmortem brain of Parkinson's disease (PD) patients. | |
| Control | normal postmortem substantia nigra tissue |
| Substantia nigra tissue from postmortem brain of normal controls. |
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):-2.7485123Number of Samples:2 / 2
| Experimental | LPS study 4 (shRNA contr.) |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated / transduced MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
ovarian tumor study 16 / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):-2.7077293Number of Samples:3 / 5
| Experimental | ovarian tumor study 16 |
| Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM). | |
| Control | normal ovarian surface epithelial cell sample |
| Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue. |
wound healing study 2 (ex vivo; DMSO) / normal skin tissue (ex vivo)
Relative Expression (log2-ratio):-2.6935215Number of Samples:3 / 3
| Experimental | wound healing study 2 (ex vivo; DMSO) |
| Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing DMSO for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 1:1000 fold dilution of DMSO. The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin. | |
| Control | normal skin tissue (ex vivo) |
| Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. |
medulloblastoma study 2 / non-tumor brain tissue
Relative Expression (log2-ratio):2.619441Number of Samples:4 / 9
| Experimental | medulloblastoma study 2 |
| Primary tumor tissue sample from the infratentorial brain of pediatric patients with large-cell anaplastic medulloblastoma. | |
| Control | non-tumor brain tissue |
| Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor. |
B-CLL study 9 (CD19+; CD5+; Wnt3a) / B-CLL study 9 (CD19+; CD5+)
Relative Expression (log2-ratio):-2.523611Number of Samples:6 / 172
| Experimental | B-CLL study 9 (CD19+; CD5+; Wnt3a) |
| CD19+ CD5+ B-cell samples from subjects with chronic lymphocytic leukemia (CLL) and treated with Wnt3a for 48 hours. It is not clear whether the concentration of Wnt3a was 5ng/ml or 50ng/ml. B-cells were isolated from peripheral blood mononuclear cells. Samples were collected from predominantly chemotherapy-naive patients representing the broad spectrum of CLL clinical heterogeneity, based on established prognostic risk factors (ZAP70 expression; degree of somatic hypermutation in the variable region of the immunoglobulin heavy chain [IGHV] gene; presence of specific CLL-associated cytogenetic abnormalities). All tumor samples were comprised of more then 95% tumor purity. | |
| Control | B-CLL study 9 (CD19+; CD5+) |
| CD19+ CD5+ B-cell samples from subjects with chronic lymphocytic leukemia (CLL). B-cells were isolated from peripheral blood mononuclear cells. Samples were collected from predominantly chemotherapy-naive patients representing the broad spectrum of CLL clinical heterogeneity, based on established prognostic risk factors (ZAP70 expression; degree of somatic hypermutation in the variable region of the immunoglobulin heavy chain [IGHV] gene; presence of specific CLL-associated cytogenetic abnormalities). All tumor samples were comprised of more then 95% tumor purity. |
immunoglobulin (IVIG) study 2 (responder) / Kawasaki disease study 2 (responder)
Relative Expression (log2-ratio):2.5222197Number of Samples:4 / 4
| Experimental | immunoglobulin (IVIG) study 2 (responder) |
| Whole blood samples from subjects with Kawasaki disease obtained 36-48 hours after treatment with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to have good response to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness. ATC code:--- | |
| Control | Kawasaki disease study 2 (responder) |
| Whole blood samples from subjects with Kawasaki disease obtained prior to therapy with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to have good response to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness. |